- Home
- BB vs VRDN Comparison
BB vs VRDN Comparison
Compare BB & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BB
- VRDN
- Stock Information
- Founded
- BB 1984
- VRDN 2006
- Country
- BB Canada
- VRDN United States
- Employees
- BB N/A
- VRDN N/A
- Industry
- BB
- VRDN Medical Specialities
- Sector
- BB
- VRDN Health Care
- Exchange
- BB Nasdaq
- VRDN Nasdaq
- Market Cap
- BB 1.5B
- VRDN 1.5B
- IPO Year
- BB 1997
- VRDN N/A
- Fundamental
- Price
- BB $2.32
- VRDN $19.62
- Analyst Decision
- BB Hold
- VRDN Strong Buy
- Analyst Count
- BB 5
- VRDN 10
- Target Price
- BB $3.39
- VRDN $37.25
- AVG Volume (30 Days)
- BB 8.6M
- VRDN 1.1M
- Earning Date
- BB 12-18-2024
- VRDN 11-12-2024
- Dividend Yield
- BB N/A
- VRDN N/A
- EPS Growth
- BB N/A
- VRDN N/A
- EPS
- BB N/A
- VRDN N/A
- Revenue
- BB $637,000,000.00
- VRDN $302,000.00
- Revenue This Year
- BB N/A
- VRDN N/A
- Revenue Next Year
- BB $7.65
- VRDN N/A
- P/E Ratio
- BB N/A
- VRDN N/A
- Revenue Growth
- BB N/A
- VRDN N/A
- 52 Week Low
- BB $2.01
- VRDN $11.40
- 52 Week High
- BB $4.44
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- BB 43.45
- VRDN 34.74
- Support Level
- BB $2.29
- VRDN $19.65
- Resistance Level
- BB $2.42
- VRDN $20.87
- Average True Range (ATR)
- BB 0.08
- VRDN 1.39
- MACD
- BB -0.00
- VRDN -0.52
- Stochastic Oscillator
- BB 25.81
- VRDN 2.07
About BB BlackBerry Limited
BlackBerry, once known for being the world's largest smartphone manufacturer, is now exclusively a software provider with a stated goal of end-to-end secure communication for enterprises. The firm provides endpoint management and protection to enterprises, specializing in regulated industries like government, as well as embedded software to the automotive, medical, and industrial markets.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.